NCT03341988View on ClinicalTrials.gov

Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 22, 2017

Primary Completion Date

January 1, 2018

Study Completion Date

May 1, 2018

Conditions
Hepatitis C
Interventions
DRUG

Ombitasvir-Paritaprevir-Ritonavir Tab 12.5-75-50 milligram

To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in ch HCV infected patients in those with CKD vs ESRD 2- Also assess duration of sustained viral response,treatment, relapse or failure of therapy in CKD vs ESRD

Trial Locations (1)

Unknown

Assiut University, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT03341988 - Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients | Biotech Hunter | Biotech Hunter